News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
The company has received five final approvals
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Subscribe To Our Newsletter & Stay Updated
